Catalyst Wire Dossier Catalyst Wire Dossier

Enhertu (trastuzumab deruxtecan)

trastuzumab deruxtecan · Daiichi Sankyo
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for Enhertu (trastuzumab deruxtecan), covering 2025-09-15 to 2026-04-14. Get the full timeline:

Most recent: Clinical Trial Update: Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene [Phase 1]

See pricing